Background. Operative mortality rates are of great interest to surgeons, patients, policy makers, and payers as a metric for quality assessment. Thirty-day mortality and discharge mortality have been presumed to capture procedure-related deaths. However, many patients die after the 30-day mark or are transferred to other facilities or to home and die there, leading to the underreporting of surgically related deaths. We hypothesized that a longer period of observation would address these concerns and provide a more accurate measure of operative mortality.
esophageal cancer, and 269 for mesothelioma. Among the different cancers and across operations, the additional mortality from day 31 to 90 (1.4%; 95% CI, 1.2% to 1.8%; n [ 111) was similar to that by day 30 (1.2%; 95% CI, 1.0% to 1.5%; n [ 95), resulting in overall 90-day mortality (2.7%; 95% CI, 2.3% to 3.1%; n [ 206) that was more than double the 30-day mortality.
Conclusions. Among patients who have undergone operations for thoracic malignancies, mortality attributable to the operation occurs beyond the first 30 postsurgical days as well as after hospital discharge. Because cancer operations constitute a large portion of general thoracic surgery, we recommend national databases consider the inclusion of 90-day mortality in their data collection. perative mortality rates are of interest to a variety of stakeholders, including surgeons, patients, policy makers, and payers, because they serve as a universal metric for the assessment of quality. The American College of Surgeons National Surgical Quality Improvement Program database defines operative mortality as any death within 30 days of an operation [1] . The Society of Thoracic Surgeons National Database includes 30-day mortality and discharge mortality, which includes any in-hospital deaths after a procedure during that hospitalization [2] .
These measures provide surgeons with a benchmark for performance, and most of the published literature considers these outcomes from the surgeon's perspective. Interest has been growing in patient-centered outcomes, most recently championed by the Institute of Medicine in its 2013 report on cancer care [3] . From the patient's perspective, 30-day and discharge mortality rates provide an important estimate of risk because they weigh the purported benefits of an operation against the potential for unintended complications and death. An accurate assessment of the risk involved in a given procedure is crucial, and 30-day mortality is the most common estimate of this operative risk.
The 30-day interval has generally been presumed to be close enough to the procedure to capture deaths attributable to it. However, others have suggested that 90 days may be more appropriate [4] [5] [6] . That Medicare reimbursement for major surgical procedures includes all care during the first 90 days after the operation highlights the belief that care, and hence risk, does not end at 30 days.
Patients with thoracic malignancies tend to be older and have more comorbid illnesses, resulting in a diminished reserve to tolerate adverse events. Critically ill postoperative patients may experience protracted hospital courses only to die after the 30-day mark, whereas others may be transferred to outside facilities and die there. Other patients may be discharged after the operation only to be readmitted with complications that lead to their death. Finally, patients may be successfully discharged and then die unexpectedly at home. None of the deaths in these scenarios would be captured in the 30-day or discharge mortality statistics. This leads to the underreporting of deaths related to the operation. In addition, the increased scrutiny of outcomes introduces a potential perverse incentive to prolong the life of a dying patient past the 30-day barrier or to transfer the patient to another facility before 30 days has passed.
We hypothesized that 30-day mortality rates underestimate the risk of early death for patients undergoing operations for thoracic malignancies. We reviewed our perioperative experience across three cancers (lung cancer, esophageal cancer, and mesothelioma) and six procedures for early death, readmissions, cause of death, and location of death.
Material and Methods
We retrospectively analyzed our prospectively maintained databases of surgical resections for lung cancer, esophageal cancer, and mesothelioma performed between January 1, 1999, and August 6, 2012, at Memorial Sloan Kettering Cancer Center. The procedures for lung cancer included sublobar resection (wedge resection/ segmentectomy), lobectomy, and pneumonectomy. Bilobectomies were included in the lobectomy group. The resections for esophageal cancer included McKeown, Ivor Lewis, and transhiatal esophagectomy. Those for mesothelioma included extrapleural pneumonectomy and pleurectomy/decortication. Patients aged 18 years or older were included in the analysis. Deaths after palliative procedures were excluded.
Data on patient deaths were obtained from the medical record-including patient records, death certificates, and family notifications-and were cross-referenced against the Social Security Death Index. Clinical characteristics were abstracted from patient records. The study was approved by the Memorial Sloan Kettering Institutional Review Board, which waived the requirement for individual consent (IRB No. WA 0134-13).
To mirror the Medicare global payment period of 90 days, perioperative deaths were examined separately from two periods: from postoperative day (POD) 0 to 30 and from POD 31 to 90. Total 90-day mortality was also calculated. For each interval, mortality was calculated as the proportion of deaths of all patients alive at the beginning of the interval. The level of significance for all tests was set at p < 0.05, and 95% confidence intervals (CIs) were generated. STATA 12 software (StataCorp LP, College Station, TX) was used to perform all statistical analyses.
Results
During the study period, 7,646 patients underwent resection for lung cancer, esophageal cancer, or mesothelioma. The median length of follow-up for the cohort was 23.3 months. The proportion lost to follow-up was 0.8% from POD 0 to 30 and 1.5% from POD 31 to 90.
Patient Characteristics
In total, 6,119 patients underwent resection for lung cancer, 1,258 underwent esophagectomy, and 269 underwent resection for mesothelioma. Patient characteristics are presented in Table 1 . More women (58%) than men underwent lung resections; however, men represented more than 75% of the esophageal and mesothelioma resections. The mean patient age was 66 years.
The median length of stay (LOS) overall, across all procedures, was 6 days. Across all patients, 3% (231 of 7,646) had an LOS exceeding 30 days. The LOS exceeded 30 days in 10% of resections for esophageal cancer and in 12% of resections for mesothelioma (Table 1) . Almost one-third of resections included a reported complication during the index hospitalization. Comorbid cardiopulmonary disease was common, with the highest prevalence of cardiac (23%) and pulmonary (34%) disease occurring among the lung cancer cohort.
Mortality Calculations
Data on perioperative mortality for POD 0 to 30 and POD 31 to 90 are presented in Table 2 . Overall, 95 deaths occurred during POD 0 to 30, and 111 deaths occurred during POD 31 to 90, resulting in a mortality rate of 1.2% (95% CI, 1.0% to 1.5%) for POD 0 to 30 and 1.4% (95% CI, 1.2% to 1.8%) for POD 31 to 90. The overall mortality rate for POD 0 to 90 was 2.7% (95% CI, 2.3% to 3.1%). For nearly all types of resections, the number of additional deaths occurring during POD 31 to 90 was similar to the number occurring during the first 30 days. Sublobar resections had the lowest mortality rate (POD 0 to 30, 0.7%; POD 31 to 90, 0.7%), and extrapleural pneumonectomy had the highest (POD 0 to 30, 2.6%; POD 31 to 90, 8.7%). The Kaplan-Meier survival curves of perioperative mortality after each type of resection are shown in Figure 1 .
Common Postoperative Complications and Causes of Death
The most common causes of death by type of disease and postoperative interval are reported in Table 3 . Isolating a single root cause of death was not always possible. In 46 patients, more than one factor contributed to death. Cause of death was determined for 75% of patients (n ¼ 154), representing 88% of deaths during POD 0 to 30 and 64% of deaths during POD 31 to 90.
Respiratory failure, sepsis, and cardiac events were the leading causes of death after thoracic resection. The cause of death in 11 patients (5%) was assessed to be progression of disease. Respiratory failure occurred as a result of pneumonia, acute respiratory distress syndrome, and aspiration, whereas sudden cardiac death/arrhythmia and myocardial infarction composed the cardiac etiologies.
Hospital Discharges, Readmissions, and Location of Death
The relative proportions of in-hospital deaths and postdischarge deaths are reported in Table 4 . Of the 206 deaths that occurred during POD 0 to 90, more than half occurred after POD 30 (111 [54%]). Similarly, more than half of the 206 deaths occurred after hospital discharge (111 [54%]). Taken together, 83 postoperative deaths (40%) would not have been counted in the 30-day or the discharge mortality figures.
Of the postdischarge deaths, nearly 50 (45%) occurred during the course of readmission to the hospital. An additional 10 (5%) occurred at hospice or at home. Location of death was unknown for 50 patients who died after hospital discharge.
Comment
The major finding in this study is that among patients who have undergone operations for thoracic malignancies, considerable mortality attributable to the operation occurs beyond the first 30 days after the procedure, as well as after initial discharge from the hospital. A substantial number of deaths occurred during POD 31 to 90, resulting in a twofold increase in mortality at 90 days (2.7%) compared with mortality at 30 days (1.2%). By examining mortality during POD 31 to 90 and the postdischarge period, we ascertained that most of the deaths during these periods were attributable to surgically related complications. With 40% of deaths during POD 0 to 90 falling outside of the 30-day or discharge definitions of operative mortality, these measures underreport the risk of early postoperative death.
Similar to the findings in this report, two recent studies focusing on pulmonary resections and operations for lung cancer found that mortality during POD 31 to 90 equaled or exceeded that during POD 0 to 30 [4, 5] . In a singleinstitution experience, older age, comorbid disease, and longer LOS were associated with death during POD 31 to 90 [4] . In an analysis of population-based data from the English National Lung Cancer Audit, mortality at 90 days (5.9%) was nearly twice that at 30 days (3%). The same results were obtained when 30-day and 90-day mortality rates were compared across eight different cancer types, including lung and esophageal cancer, in a populationbased analysis from the Netherlands [6] . However, none of these studies included patients with mesothelioma, which we found had a 90-day mortality four times that at 30 days. A potential caveat to our findings is that cancer patients are at risk of dying of their disease. In the above-mentioned study of pulmonary resections, 19 of 44 deaths between POD 31 and 90 were attributed to "natural causes," which included disease progression [4] . However, the causes of death of most of the patients in our study who died early were related to complications associated with the procedure. Only 11 patients were identified to have died of cancer, which suggests that disease progression made a limited contribution to the deaths that occurred during POD 31 to 90. Although early death from disease progression without the presence of treatment-related complications is possible, it should remain an unexpected outcome among patients who have been properly staged and offered resection with the promise of cure.
Isolating a single root cause of death can be challengingindeed, more than one cause was identified in 46 patients. Nevertheless, respiratory events, sepsis, and cardiac events were by far the most common causes of death across the three cancers in this study. Respiratory failure was the leading cause, with pneumonia, aspiration, acute respiratory distress syndrome, and pneumonitis serving as the primary causes. Not surprisingly, in the study by Bryant and colleagues [4] , respiratory events were the most common cause of early death among patients who underwent pulmonary resections. Sepsis resulted from anastomotic leaks, line infections, pneumonia, empyemas, and abscesses. Cardiac events included arrhythmias, sudden cardiac death, and myocardial infarctions.
Strikingly, more than half of the deaths during POD 0 to 90 occurred after discharge from the initial hospitalization. Of the patients who died during this period, 55% (60 of 110) were readmitted to the hospital and ultimately died there (n ¼ 50) or were subsequently discharged to hospice or home and died there (n ¼ 10). Some patients may express a desire to die at home, which may affect discharge practices, subsequent readmission rates, and the location of death. No information about location of death was available for 50 of the patients who died after discharge. The decline in the use of autopsy further hinders our ability to distill root causes of death. Presumably, many of these patients died suddenly at home, but this lack of information highlights the challenges of obtaining detailed follow-up information without the systems infrastructure that could be provided by efforts like the National Surgical Quality Improvement Program and The Society of Thoracic Surgeons databases.
That more than half of the deaths during POD 0 to 90 occurred after discharge raises the question of whether anything might have been done differently at the time of the discharge evaluation or immediately after discharge to prevent these deaths. Bryant and colleagues [4] found that among patients who had undergone pulmonary resections, sudden death was the most common cause of death at home after discharge. Older age, prolonged LOS, hypertension, and coronary disease were identified as predictors of postdischarge death between POD 31 and 90 [4] . Perhaps closer monitoring after discharge, with earlier and repeated follow-up visits, better coordination with primary physicians, and regular home visits by care providers in these high-risk patients could lead to earlier detection of problems and improved outcomesbut there is no evidence yet to support this strategy.
Implicit in the choice of 30 days as the cutoff point for postoperative outcomes is the idea that deaths occurring after this time are less likely to be related to the treatment and that the inclusion of unrelated deaths might artificially inflate the reported morality rate. First, although patients may possibly die of incidental causes unrelated to the operation during the extended period, the cumulative mortality from such events would be far lower than our observed rate of 1.4% and would thus be unlikely to meaningfully alter the reported mortality rate.
Second, an examination of other, nonsurgical treatments provides a point of comparison. For sicker patients unfit for an operation, stereotactic body radiotherapy is an alternative to sublobar resection for localized lung cancer. Yet sublobar resection had a 90-day mortality of 1.4% in our series and 2.4% in a prospective trial (American College of Surgeons Oncology Group Z4032), whereas stereotactic body radiotherapy had a 90-day mortality of 0% in two separate studies, including a prospective trial (Radiation Therapy Oncology Group 0236) [7, 8] .
Because distinguishing between deaths from the operation from those from other causes becomes more difficult with increasing time from the operation, the survival curves presented cannot be used to reliably identify a time when operative mortality levels off. As the time after the operation increases, the number of deaths represented by the operation is likely to diminish and the proportion of deaths from other causes will increase. However, the curves clearly show that considerable mortality continues to occur after the 30-day mark.
Limitations of our study include the retrospective, single-institution analysis. Future efforts to confirm these observations in broader, population-based data sets are warranted. Other limitations are related to loss to followup and the difficulties previously mentioned in obtaining accurate data on the cause of death. The inclusion of 90-day follow-up data in national outcomes databases would help address this knowledge gap.
Our analysis was confined to operations for thoracic malignancies. It is necessary to replicate our results in nonthoracic cancer operations and major operations for benign diseases. It is possible that a 90-day observation period may be relevant for only a subset of major procedures. For payers and policy makers, changes in the interval used to define operative mortality may affect comparisons of quality and how care is compensated. Johnson and colleagues [9] found that hospital rankings changed significantly when postoperative mortality was measured beyond 30 days. From the patient's perspective, though, the fact that as many or more patients died in the second and third months after surgery as in the first month means that the oft-quoted 30-day mortality does not fully capture their risk. Patients with thoracic malignancies accept the increased risk of death in the immediate period after the operation in hopes of a longer-term benefit. Therefore, more accurate accounting of postoperative mortality has important ramifications for patients-most notably in the calculation of risks vs benefits when making treatment decisions.
Because cancer operations constitute a large portion of the practice of general thoracic surgery, we recommend that national databases such as The Society of Thoracic Surgeons General Thoracic Surgery Database and the National Surgical Quality Improvement Program database consider the inclusion of 90-day mortality in their data collection. We anticipate that doing so will provide all stakeholders, including patients, clinicians, policy makers, and payers, with a more complete assessment of the risk of early mortality after surgical resection for thoracic malignancies.
points are false, and what you are reporting is really the reality that we are not decreasing mortality in some of the more complicated patients.
DR MCMILLAN: Thank you for the question. Delineating exactly the destination for our patients who were discharged and subsequently died, I do not have that information at my fingertips, although, yes, a large number went to long-term acute care hospitals and a smaller number did go to ventilator facilities or rehab facilities as well. That would be a part of our manuscript, the exact destinations.
DR YOLONDA L. COLSON (Boston, MA): It is interesting that if you look at pneumonectomies vs extrapleural pneumonectomies, in the pneumonectomies, the greater proportion of the mortality was in the first 30 days, whereas in extrapleural pneumonectomies, it was between 31 and 90 days. Is that due to disease progression mostly in that specific group compared to the others?
DR MCMILLAN: When we looked at patients who had a resection for mesothelioma, we were able to identify one patient expiring from disease progression in that second interval. It is unclear.
DR COLSON: They are both pneumonectomies and clearly they are different, but there is more of a late death component to the extrapleural pneumonectomies than the pneumonectomies. Do you have insight into why that is? DR MCMILLAN: Some were, yes, and that did not appear in our individual record analysis. We did not find specific cases of deaths clearly attributable to the adjuvant therapy itself, at least not currently.
DR HUANG: Let me just address that point. I think the question about adjuvant therapy is obviously important in these patients who have had cancer resections, but the interesting thing about these early deaths was that the vast majority of them were so ill and they were in the hospital and they never actually made it to adjuvant therapy. So a very small fraction of these deaths could potentially be attributable to adjuvant therapy. The vast majority of these patients were in the hospital either prior to discharge and in the intensive care unit with a typical multisystem organ failure-type scenario or they went home, were discharged, and felt to be in good shape, but then either suddenly dropped dead outside or got readmitted to a local hospital and never made it back to our hospital.
